Full-Time

Territory Account Manager

Confirmed live in the last 24 hours

Biomodal

Biomodal

51-200 employees

Develops genomic technologies for life sciences

No salary listed

Senior

New York, NY, USA

Must live in the North East, ideally with an understanding of the omics user base in that area.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Hubspot
Requirements
  • Bachelor’s degree in life sciences (e.g biology, molecular biology, etc)
  • Proven experience in Life Sciences sales/Account Management, preferably in NexGen Sequencing or multiomic technologies
  • Strong interpersonal, negotiation, and presentation skills.
  • Experience in CRM tools such as SFDC or HubSpot
  • Knowledge in the fields of cancer research, neuronal disorders, aging and/or reproductive health a plus
  • Must live in the North East, ideally with an understanding of the omics user base in that area
  • Exceptional communication skills in English – written and oral; must be a very strong public speaker.
  • Exceptional organizational skills – planning and follow through, track record of successfully managing many competing priorities at one time
  • Self-starter, solution oriented, collaborative, team-player; a “can-do” and “customer first” mentality
  • Glowing references for previous work in a relevant role - please be prepared to submit references that will be contacted by the hiring manager and HR.
Responsibilities
  • Manage and grow a portfolio of existing accounts within the assigned geography.
  • Identify, develop, and close new business opportunities to achieve sales targets.
  • Build and maintain strong relationships with key-decision makers and stakeholders.
  • Conduct regular customer visits to ensure customer satisfaction and identify upsell opportunities.
  • Develop a deep understanding of the customer’s needs and positions solutions to meet those needs
  • Work cross-functionally with internal teams (marketing, product, customer support) to ensure customer satisfaction.
  • Maintain accurate records of all sales activities in CRM software.
  • Attend industry events, trade shows and networking opportunities to build awareness
  • Develop, execute, monitor and report at an executive level, a commercial strategy to grow the territory
  • Develop and manage a growing opportunity pipeline and use CRM software effectively
  • Partner closely with marketing, customer solutions and executive team to evangelize the technology and develop customers advocates
  • Manage key accounts, KOLs and strategic collaborations to achieve commercial and corporate-level objectives
  • Average travel expectations: 50-60% time; mostly within North America but with the possibility to travel internationally if needed.
  • Other responsibilities TBD depending on the evolving needs of the company
Desired Qualifications
  • Knowledge in the fields of cancer research, neuronal disorders, aging and/or reproductive health a plus

Biomodal develops technologies designed to assist life scientists and clinical developers in their research. Their platform enables the capture of the 6-base genome, which helps in understanding the complex interactions within cells. The technology integrates seamlessly with existing laboratory setups, combining a pre-sequencing workflow with post-sequencing data analysis. This allows users to obtain precise genetic and epigenetic information from a single sample in one run. Biomodal stands out from competitors by offering a comprehensive solution that simplifies the sequencing process while providing detailed insights into cellular dynamics. The company's goal is to enhance research capabilities in genetics and epigenetics, ultimately contributing to advancements in life sciences.

Company Size

51-200

Company Stage

Series D

Total Funding

$185.1M

Headquarters

Cambridge, United Kingdom

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • AI integration in multiomics enhances predictive models and biological insights.
  • Machine learning aids in novel biomarker detection, supporting personalized medicine.
  • Rising demand for cfDNA analysis boosts Biomodal's non-invasive diagnostic solutions.

What critics are saying

  • Rapid technological advancements may render Biomodal's offerings obsolete without continuous innovation.
  • New board appointments could lead to strategic shifts disrupting current operations.
  • Pressure from $88M Series D financing may lead to rushed product developments.

What makes Biomodal unique

  • Biomodal's duet evoC offers 6-base genome sequencing, enhancing disease detection capabilities.
  • The technology distinguishes between 5mC and 5hmC, providing detailed epigenetic insights.
  • Biomodal integrates genetic and epigenetic data, offering comprehensive multiomic solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Paid Vacation

Performance Bonus

401(k) Retirement Plan

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Wire
Feb 5th, 2024
Biomodal Delivers The 6-Base Genome With A Powerful New Multiomic Solution, Duet Evoc

CAMBRIDGE, England--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC). The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, G, C, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), on the same DNA molecule. This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA). The advanced 6-base genome data enables the exploration of epigenetic mechanisms of gene regulation through methylation and hydroxymethylation. Researchers now are able to obtain an accurate measurement of 5mC and 5hmC, integrated into local genetic context, with 95% of bases above Q30 and 50% with accuracy above Q40. By measuring multiple modes of biology from a single low-input DNA sample in a single experiment, researchers can use the comprehensive data to build predictive models of gene expression, chromatin accessibility, and enhancer status to better understand the biological mechanisms that link genotype to phenotype

GenomeWeb
Apr 14th, 2023
People in the News at Adaptive Biotechnologies, Biocartis, Sherlock Biosciences, Epigenomics, More | GenomeWeb

Biomodal, formerly Cambridge Epigenetix, has appointed Dennis Yuk Ming Lo to its scientific advisory board and Omead Ostadan to its board of directors.

New Science Ventures
Jun 14th, 2022
Cambridge Epigenetix will hire Peter J. Fromen as Chief Executive Officer on Jul 18th 22'.

Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022.

Business Weekly
Nov 4th, 2021
Cambridge Epigenetix raises $88m in Series D round

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising...

ExploreBit
Nov 2nd, 2021
Cambridge Epigenetix received financing of $88M in Series D financing on Nov 2nd 21'.

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million.